- Home
- KC vs APLS Comparison
KC vs APLS Comparison
Compare KC & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KC | APLS |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.7B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | KC | APLS |
|---|---|---|
| Price | $14.43 | $22.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 20 |
| Target Price | $17.50 | ★ $32.16 |
| AVG Volume (30 Days) | 1.3M | ★ 3.7M |
| Earning Date | 03-18-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.36 |
| Revenue | ★ $1,268,313,014.00 | $1,016,397,000.00 |
| Revenue This Year | $25.79 | $31.31 |
| Revenue Next Year | $17.31 | N/A |
| P/E Ratio | ★ N/A | $63.05 |
| Revenue Growth | 24.11 | ★ 42.11 |
| 52 Week Low | $10.29 | $16.10 |
| 52 Week High | $22.26 | $30.48 |
Technical Indicators
Market Signals| Indicator | KC | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 45.13 |
| Support Level | $12.75 | $22.29 |
| Resistance Level | $13.47 | $23.69 |
| Average True Range (ATR) | 0.61 | 1.14 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 81.02 | 32.17 |
Price Performance
Historical ComparisonAbout KC Kingsoft Cloud Holdings Limited
Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.